Table of Contents Author Guidelines Submit a Manuscript
Experimental Diabetes Research
Volume 2010, Article ID 617052, 12 pages
http://dx.doi.org/10.1155/2010/617052
Research Article

Glucose Regulation of Thrombospondin and Its Role in the Modulation of Smooth Muscle Cell Proliferation

Division of Endocrinology, University of North Carolina, CB# 7170, 5030 Burnett Womack, Chapel Hill, NC 27599-7170, USA

Received 1 February 2010; Revised 5 April 2010; Accepted 16 April 2010

Academic Editor: Toshiyasu Sasaoka

Copyright © 2010 Laura A. Maile et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. I. Jones, T. Prevette, A. Gockerman, and D. R. Clemmons, “Ligand occupancy of the αVβ3 integrin is necessary for smooth muscle cells to migrate in response to insulin-like growth factor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 6, pp. 2482–2487, 1996. View at Publisher · View at Google Scholar · View at Scopus
  2. B. Cercek, M. C. Fishbein, J. S. Forrester, R. H. Helfant, and J. A. Fagin, “Induction of insulin-like growth factor I messenger RNA in rat aorta after balloon denudation,” Circulation Research, vol. 66, no. 6, pp. 1755–1760, 1990. View at Google Scholar · View at Scopus
  3. P. Hayry, M. Myllarniemi, E. Aavik et al., “Stabile D-peptide analog of insulin-like growth factor-1 inhibits smooth muscle cell proliferation after carotid ballooning injury in the rat,” FASEB Journal, vol. 9, no. 13, pp. 1336–1344, 1995. View at Google Scholar · View at Scopus
  4. L. A. Maile, B. E. Capps, Y. Ling, G. Xi, and D. R. Clemmons, “Hyperglycemia alters the responsiveness of smooth muscle cells to insulin-like growth factor-I,” Endocrinology, vol. 148, no. 5, pp. 2435–2443, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. L. A. Maile, J. Badley-Clarke, and D. R. Clemmons, “The association between integrin-associated protein and SHPS-1 regulates insulin-like growth factor-I receptor signaling in vascular smooth muscle cells,” Molecular Biology of the Cell, vol. 14, no. 9, pp. 3519–3528, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. L. A. Maile, B. E. Capps, E. C. Miller et al., “Glucose regulation of integrin-associated protein cleavage controls the response of vascular smooth muscle cells to insulin-like growth factor-I,” Molecular Endocrinology, vol. 22, no. 5, pp. 1226–1237, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. A.-G. Gao, F. P. Lindberg, M. B. Finn, S. D. Blystone, E. J. Brown, and W. A. Frazier, “Integrin-associated protein is a receptor for the C-terminal domain of thrombospondin,” The Journal of Biological Chemistry, vol. 271, no. 1, pp. 21–24, 1996. View at Publisher · View at Google Scholar · View at Scopus
  8. L. A. Maile and D. R. Clemmons, “Integrin-associated protein binding domain of thrombospondin-1 enhances insulin-like growth factor-I receptor signaling in vascular smooth muscle cells,” Circulation Research, vol. 93, no. 10, pp. 925–931, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. L. A. Maile, B. E. Capps, E. C. Miller, A. W. Aday, and D. R. Clemmons, “Integrin-associated protein association with src homology 2 domain containing tyrosine phosphatase substrate 1 regulates IGF-i signaling in vivo,” Diabetes, vol. 57, no. 10, pp. 2637–2643, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. L. A. Maile, W. H. Busby, T. C. Nichols et al., “A monoclonal antibody against alphaVbeta3 integrin inhibits development of atherosclerotic lesions in diabetic pigs,” Science Translational Medicine, vol. 2:18ra11, no. 18, p. 18ra11, 2010. View at Google Scholar
  11. Y. Ling, L. A. Maile, J. Lieskovska, J. Badley-Clarke, and D. R. Clemmons, “Role of SHPS-1 in the regulation of insulin-like growth factor I-stimulated Shc and mitogen-activated protein kinase activation in vascular smooth muscle cells,” Molecular Biology of the Cell, vol. 16, no. 7, pp. 3353–3364, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. J. I. Jones, A. Gockerman, W. H. Busby Jr., C. Camacho-Hubner, and D. R. Clemmons, “Extracellular matrix contains insulin-like growth factor binding protein- 5: potentiation of the effects of IGF-I,” Journal of Cell Biology, vol. 121, no. 3, pp. 679–688, 1993. View at Google Scholar · View at Scopus
  13. Y. Ling, L. A. Maile, J. Badley-Clarke, and D. R. Clemmons, “DOK1 mediates SHP-2 binding to the αVβ3 integrin and thereby regulates insulin-like growth factor I signaling in cultured vascular smooth muscle cells,” The Journal of Biological Chemistry, vol. 280, no. 5, pp. 3151–3158, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Radhakrishnan, L. A. Maile, Y. Ling, L. M. Graves, and D. R. Clemmons, “Insulin-like growth factor-I stimulates Shc-dependent phosphatidylinositol 3-kinase activation via Grb2-associated p85 in vascular smooth muscle cells,” The Journal of Biological Chemistry, vol. 283, no. 24, pp. 16320–16331, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Imai and D. R. Clemmons, “Roles of phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways in stimulation of vascular smooth muscle cell migration and deoxyribonucleic acid synthesis by insulin-like growth factor-I,” Endocrinology, vol. 140, no. 9, pp. 4228–4235, 1999. View at Google Scholar · View at Scopus
  16. E. Brown, L. Hooper, T. Ho, and H. Gresham, “Integrin-associated protein: a 50-kD plasma membrane antigen physically and functionally associated with integrins,” Journal of Cell Biology, vol. 111, no. 6, part 1, pp. 2785–2794, 1990. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Ling, L. A. Maile, and D. R. Clemmons, “Tyrosine phosphorylation of the β3-subunit of the αVβ3 integrin is required for membrane association of the tyrosine phosphatase SHP-2 and its further recruitment to the insulin-like growth factor I receptor,” Molecular Endocrinology, vol. 17, no. 9, pp. 1824–1833, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Bein and M. Simons, “Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity,” The Journal of Biological Chemistry, vol. 275, no. 41, pp. 32167–32173, 2000. View at Google Scholar · View at Scopus
  19. M. Sajid, Z. Hu, H. Guo, H. Li, and G. A. Stouffer, “Vascular expression of integrin-associated protein and thrombospondin increase after mechanical injury,” Journal of Investigative Medicine, vol. 49, no. 5, pp. 398–406, 2001. View at Google Scholar · View at Scopus
  20. O. I. Stenina, I. Krukovets, K. Wang et al., “Increased expression of thrombospondin-1 in vessel wall of diabetic Zucker rat,” Circulation, vol. 107, no. 25, pp. 3209–3215, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Zhou, M. H. Poczatek, K. H. Berecek, and J. E. Murphy-Ullrich, “Thrombospondin 1 mediates angiotensin II induction of TGF-β activation by cardiac and renal cells under both high and low glucose conditions,” Biochemical and Biophysical Research Communications, vol. 339, no. 2, pp. 633–641, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. X.-M. Zhang, F. Shen, Z.-Y. Xv, Z.-Y. Yan, and S. Han, “Expression changes of thrombospondin-1 and neuropeptide Y in myocardium of STZ-induced rats,” International Journal of Cardiology, vol. 105, no. 2, pp. 192–197, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Belmadani, J. Bernal, C.-C. Wei et al., “A thrombospondin-1 antagonist of transforming growth factor-β activation blocks cardiomyopathy in rats with diabetes and elevated angiotensin II,” American Journal of Pathology, vol. 171, no. 3, pp. 777–789, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Raman, I. Krukovets, T. E. Marinic, P. Bornstein, and O. I. Stenina, “Glycosylation mediates up-regulation of a potent antiangiogenic and proatherogenic protein, thrombospondin-1, by glucose in vascular smooth muscle cells,” The Journal of Biological Chemistry, vol. 282, no. 8, pp. 5704–5714, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Bhattacharyya, T. E. Marinic, I. Krukovets, G. Hoppe, and O. I. Stenina, “Cell type-specific post-transcriptional regulation of production of the potent antiangiogenic and proatherogenic protein thrombospondin-1 by high glucose,” The Journal of Biological Chemistry, vol. 283, no. 9, pp. 5699–5707, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. P. J. McKeown Longo, R. Hanning, and D. F. Mosher, “Binding and degradation of platelet thrombospondin by cultured fibroblasts,” Journal of Cell Biology, vol. 98, no. 1, pp. 22–28, 1984. View at Google Scholar · View at Scopus
  27. H. Chen, J. Sottile, D. K. Strickland, and D. F. Mosher, “Binding and degradation of thrombospondin-1 mediated through heparan sulphate proteoglycans and low-density-lipoprotein receptor-related protein: localization of the functional activity to the trimeric N-terminal heparin-binding region of thrombospondin-1,” Biochemical Journal, vol. 318, no. 3, pp. 959–963, 1996. View at Google Scholar · View at Scopus
  28. H. Chen, D. K. Strickland, and D. F. Mosher, “Metabolism of thrombospondin 2: binding and degradation by 3T3 cells and glycosaminoglycan-variant Chinese hamster ovary cells,” The Journal of Biological Chemistry, vol. 271, no. 27, pp. 15993–15999, 1996. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Yamanouchi, A. Takatori, E. Nishida, S. Kawamura, and Y. Yoshikawa, “Expression of lipoprotein receptors in the aortic walls of diabetic APA hamsters,” Experimental Animals, vol. 51, no. 1, pp. 33–41, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Hong, L. P. Liu, J. M. Liao et al., “Downregulation of LPR1 at the blood-brain barrier in streptozotocin-induced diabetic mice,” Neuropharmacology, vol. 56, no. 6-7, pp. 1054–1059, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Brownlee, “The pathobiology of diabetic complications: a unifying mechanism,” Diabetes, vol. 54, no. 6, pp. 1615–1625, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Amos, M. Mut, C. G. DiPierro et al., “Protein kinase C-α-mediated regulation of low-density lipoprotein receptor-related protein and urokinase increases astrocytoma invasion,” Cancer Research, vol. 67, no. 21, pp. 10241–10251, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. J. E. Donahue, S. L. Flaherty, C. E. Johanson et al., “RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease,” Acta Neuropathologica, vol. 112, no. 4, pp. 405–415, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. J. F. McDonald, A. Zheleznyak, and W. A. Frazier, “Cholesterol-independent interactions with CD47 enhance αvβ3 avidity,” The Journal of Biological Chemistry, vol. 279, no. 17, pp. 17301–17311, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. D. J. Dorahy, R. F. Thorne, J. V. Fecondo, and G. F. Burns, “Stimulation of platelet activation and aggregation by a carboxyl- terminal peptide from thrombospondin binding to the integrin-associated protein receptor,” The Journal of Biological Chemistry, vol. 272, no. 2, pp. 1323–1330, 1997. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Chung, A.-G. Gao, and W. A. Frazier, “Thrombspondin acts via integrin-associated protein to activate the platelet integrin α(IIb)β3,” The Journal of Biological Chemistry, vol. 272, no. 23, pp. 14740–14746, 1997. View at Publisher · View at Google Scholar · View at Scopus